Related Experiment Videos
Short-lived effect of (Des-Tyr)-gamma-endorphin in schizophrenia
Abstract:
Des-tyrosine-gamma-endorphin (DT gamma E) has been reported to alleviate symptoms of schizophrenia. Attempting to replicate those reports, we administered 1 mg of DT gamma E, i.m., for 8 consecutive days to nine patients meeting the DSM-III criteria for schizophrenia. Patients in this double-blind, crossover, and placebo-controlled study showed a statistically significant, but clinically modest improvement. The improvement was detectable during the first several days of the DT gamma E treatment; the symptoms then returned to baseline level in spite of continued doses of DT gamma E. Testing the metabolism of DT gamma E in the patients' plasma, we found a high rate of formation and of degradation, but the metabolic rates were not related to clinical symptoms.
Insights
Des-tyrosine-gamma-endorphin (DT gamma E) showed modest, short-lived improvements in schizophrenia symptoms. Further research is needed to understand its efficacy and metabolism in patients.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Schizophrenia is a complex mental disorder with limited treatment options.
- Des-tyrosine-gamma-endorphin (DT gamma E) has shown potential in alleviating schizophrenia symptoms.
- Replication studies are crucial for validating therapeutic claims.
Purpose of the Study:
- To investigate the efficacy of DT gamma E in treating schizophrenia.
- To assess the clinical effects and metabolic profile of DT gamma E in patients.
Main Methods:
- A double-blind, crossover, placebo-controlled study was conducted.
- Nine patients meeting DSM-III criteria for schizophrenia received 1 mg of DT gamma E intramuscularly daily for 8 days.
- Plasma DT gamma E levels and metabolic rates were analyzed.
Main Results:
- A statistically significant but clinically modest improvement in schizophrenia symptoms was observed.
- Symptom improvement was transient, lasting only the first few days of treatment.
- High rates of DT gamma E formation and degradation were found in patient plasma, unrelated to clinical outcomes.
Conclusions:
- DT gamma E demonstrates a temporary therapeutic effect in schizophrenia patients.
- The rapid metabolism of DT gamma E may limit its clinical utility.
- Further investigation into DT gamma E's pharmacokinetics and pharmacodynamics is warranted.